Correlation Engine 2.0
Clear Search sequence regions

  • adult (2)
  • humans (1)
  • interferon (10)
  • non hodgkin lymphoma (1)
  • patients (2)
  • phase (1)
  • sars cov (2)
  • Sizes of these terms reflect their relevance to your search.

    Pegylated interferon lambda substantially reduced the risk of COVID-19-related hospitalizations or emergency room visits in a recent phase 3, multi-center, randomized, double-blind, placebo-controlled study of high-risk, non-hospitalized adult patients with SARS-CoV-2 infection compared to treatment with placebo. Interferons are a family of signaling molecules produced as part of the innate immune response to viral infections. The administration of exogenous interferon may limit disease progression in patients with COVID-19. Interferons have been used to treat viral infections, including hepatitis B and hepatitis C, and malignancies such as non-Hodgkin's lymphoma, as well as the autoimmune condition multiple sclerosis. This manuscript examines what is known about the role of interferon lambda in the treatment of COVID-19, including potential limitations, and explores how this approach may be used in the future.


    Matthew W McCarthy. Interferon lambda as a potential treatment for COVID-19. Expert opinion on biological therapy. 2023 May;23(5):389-394

    Expand section icon Mesh Tags

    Expand section icon Substances

    PMID: 37147857

    View Full Text